Literature DB >> 14983969

European Randomized Study of Screening for Prostate Cancer: achievements and presentation.

M J Roobol1, F H Schröder.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14983969     DOI： 10.1111/j.1464-410x.2003.4698x.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  11 in total

1.  Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Luca Incrocci; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2017-05-19       Impact factor: 7.842

2.  The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

Authors:  Eveline A M Heijnsdijk; Jan Adolfsson; Anssi Auvinen; Monique J Roobol; Jonas Hugosson; Harry J de Koning
Journal:  Eur Urol       Date:  2019-04-26       Impact factor: 20.096

3.  DNA integrity as biomarker in pancreatic cyst fluid.

Authors:  Wesley K Utomo; Vincent T Janmaat; Auke P Verhaar; Jérôme Cros; Philippe Lévy; Philippe Ruszniewski; Mirella S Vredenbregt-van den Berg; Guido Jenster; Marco J Bruno; Henri Braat; Gwenny M Fuhler; Maikel P Peppelenbosch
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 4.  The ERSPC Study: Quality Takes Time and Perseverance.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Clin Chem       Date:  2018-11-20       Impact factor: 8.327

5.  Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.

Authors:  Donna Pauler Ankerst; Ryan Miyamoto; Prakash Vijay Nair; Brad H Pollock; Ian M Thompson; Dipen J Parekh
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

6.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Esther I Verhoef; Ewout W Steyerberg; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2016-03-04       Impact factor: 7.842

7.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

8.  Feasibility of familial PSA screening: psychosocial issues and screening adherence.

Authors:  J Sweetman; M Watson; A Norman; Z Bunstead; P Hopwood; J Melia; S Moss; R Eeles; D Dearnaley; C Moynihan
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

9.  Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment.

Authors:  E W de Bekker-Grob; M C J Bliemer; B Donkers; M-L Essink-Bot; I J Korfage; M J Roobol; C H Bangma; E W Steyerberg
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

10.  Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens.

Authors:  L Lucia Rijstenberg; Tim Hansum; Eva Hollemans; Charlotte F Kweldam; Intan P Kümmerlin; Chris H Bangma; Theodorus H van der Kwast; Monique J Roobol; Geert J L H van Leenders
Journal:  Histopathology       Date:  2020-09-11       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.